ABACHEM(SZ:300261)2023-07-21 16:00Financial Performance - The company reported a total revenue of RMB 954,685,571 for the year 2022, with a cash dividend of RMB 0.5 per 10 shares to all shareholders[5]. - The company's operating revenue for 2022 was CNY 2,000,975,899.68, a decrease of 3.42% compared to CNY 2,071,740,062.67 in 2021[22]. - Net profit attributable to shareholders increased by 11.60% to CNY 202,948,039.69 from CNY 181,849,264.51 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 54.30% to CNY 225,892,277.97, compared to CNY 146,401,786.78 in 2021[22]. - The total revenue for the reporting period was CNY 2,000.98 million, a decrease of 3.42% compared to the previous year[47]. - The net profit attributable to shareholders of the listed company was CNY 202.95 million, an increase of 11.60% year-on-year[47]. Market and Product Development - The company plans to expand its market presence and enhance its product offerings through new product development and technological advancements[5]. - The company focuses on providing CDMO services for multinational pesticide and pharmaceutical companies, emphasizing process development and optimization for key intermediates[35]. - The company is actively engaged in contract development and manufacturing (CDMO) services, catering to the pharmaceutical sector[15]. - The company has a designed capacity of 9,320 tons for pesticide intermediates and active ingredients, with a utilization rate of 66.58%[39]. - The company is currently constructing additional capacity of 700 tons for pesticide intermediates and 290 tons for pharmaceutical intermediates[39]. Research and Development - The company has invested significantly in R&D, leading to the successful commercialization of several patented products[41]. - The company’s R&D investment ratio is among the top in the industry, enhancing its competitive edge in various technical fields[45]. - The company is focused on expanding its product registration portfolio, with several products having registration validity extending into 2028, such as 95% Thiamethoxam and 98% Flupyradifurone[43]. - The company is committed to developing low-toxicity pesticides, with products like 98.5% Fluoropyrimidine and 95% Fluorosilicon showing significant efficacy against various pests[42]. Governance and Compliance - The company has established a robust governance structure, with all board members present for the report's approval[5]. - The company emphasizes its commitment to maintaining the accuracy and completeness of its financial reports, ensuring transparency for investors[5]. - The company has a governance structure in place with independent directors and a clear separation of roles among board members[133]. - The company has maintained compliance with relevant laws and regulations, ensuring that all shareholders, especially minority shareholders, can exercise their rights[125]. Environmental Responsibility - The company is committed to environmental and social responsibility, as outlined in its annual report[5]. - The company adheres to various environmental protection laws and regulations, ensuring compliance in its production processes[165]. - The company has obtained pollution discharge permits valid until December 2025 and November 2027 for its subsidiaries, demonstrating commitment to environmental standards[166]. - The company has implemented continuous monitoring of emissions, ensuring compliance with air quality standards[173]. Risk Management - The company has identified potential risks that could impact its operations and has outlined corresponding countermeasures in its management discussion[5]. - The company faces risks from macroeconomic fluctuations and stringent environmental policies, which may impact financial performance[119]. - To mitigate risks, the company will enhance its risk management capabilities and invest in environmental compliance measures[120]. Shareholder Engagement - The company conducted three temporary shareholder meetings and one annual shareholder meeting in 2022, with investor participation rates of approximately 29%[130]. - The company has a commitment to transparency in its reporting and governance practices, as evidenced by the detailed disclosures in its annual report[134]. - The company reported a cash dividend of RMB 0.5 per 10 shares, totaling RMB 47,734,278.55, which accounted for 100% of the profit distribution[156]. Strategic Partnerships and Acquisitions - The company is exploring potential acquisitions to enhance its product portfolio and market presence, targeting companies with complementary technologies[139]. - A new strategic partnership has been established with a leading technology firm to co-develop innovative solutions, expected to launch by mid-2024[139]. Employee Management - The total number of employees at the end of the reporting period was 1,038, with 191 in the parent company and 847 in major subsidiaries[151]. - The company has a performance-oriented salary management system to enhance employee motivation and align with market standards[153]. - The company emphasizes continuous employee training to improve professional skills and management capabilities[154].